Physician profile
Brea Swihart
NPI 1659669042
$5,180.62
in general payments reported to CMS, 2019-2025
22 companies · $1,400 in 2025
The $1,400 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $758 · 2022: $1,062 · 2023: $1,350 · 2024: $610 · 2025: $1,400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,463 · Consulting Fee: $800 · Education: $97.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,462.83 |
| Consulting Fee | $800.00 |
| Education | $97.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,189.05 | 2021-2025 | |
| Celltrion USA INC. | $820.41 | 2024-2025 | Zymfentra |
| Gilead Sciences, INC. | $573.55 | 2022-2025 | Epclusa, Livdelzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $505.46 | 2021-2025 | Xifaxan |
| Janssen Biotech, INC. | $451.83 | 2021-2024 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $347.61 | 2021-2025 | Entyvio |
| Madrigal Pharmaceuticals | $250.25 | 2025 | Rezdiffra |
| Novo Nordisk INC | $166.26 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Intercept Pharmaceuticals, INC. | $138.13 | 2021-2024 | |
| Apollo Endosurgery US INC | $134.31 | 2023 | Overstitch Endoscopic Suturing System |
| Lilly USA, LLC | $131.83 | 2023-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $102.29 | 2023-2024 | Dupixent |
| Nestle Healthcare Nutrition INC. | $99.65 | 2021-2023 | |
| Celgene Corporation | $59.74 | 2021-2023 | Zeposia |
| Pfizer INC. | $49.75 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $32.66 | 2025 | Zenpep |
| Ipsen Biopharmaceuticals, INC | $29.04 | 2025 | Iqirvo |
| Ethicon US, LLC | $25.91 | 2022 | |
| Merck Sharp & Dohme LLC | $21.80 | 2021 | |
| Mallinckrodt Hospital Products INC. | $17.45 | 2023 | Terlivaz |
| Genzyme Corporation | $16.84 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.80 | 2023 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brea Swihart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.